Literature DB >> 21508690

Revised FIGO staging system for endometrial cancer.

Sharyn N Lewin1.   

Abstract

In 1988 the International Federation of Gynecologists and Obstetricians (FIGO) developed a surgical staging system for endometrial cancer. The FIGO staging system was recently revised in 2009 to reflect our growing understanding of the natural history of endometrial cancer. In this review, we describe the revised 2009 FIGO staging system for tumors of the uterine corpus and examine the effect of the new changes in the staging criteria.

Entities:  

Mesh:

Year:  2011        PMID: 21508690     DOI: 10.1097/GRF.0b013e3182185baa

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  28 in total

1.  ERM/ETV5 and RUNX1/AML1 expression in endometrioid adenocarcinomas of endometrium and association with neoplastic progression.

Authors:  Vanessa Paiva Leite de Sousa; Claudia Bessa Pereira Chaves; Janina Ferreira Loureiro Huguenin; Fábio Carvalho de Barros Moreira; Bruno Souza Bianchi de Reis; Leila Chimelli; Anke Bergmann; Tatiana de Almeida Simão; Luis Felipe Ribeiro Pinto
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

2.  Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

Authors:  Daniela Matei; Virginia Filiaci; Marcus E Randall; David Mutch; Margaret M Steinhoff; Paul A DiSilvestro; Katherine M Moxley; Yong M Kim; Matthew A Powell; David M O'Malley; Nick M Spirtos; William Small; Krishnansu S Tewari; William E Richards; John Nakayama; Ursula A Matulonis; Helen Q Huang; David S Miller
Journal:  N Engl J Med       Date:  2019-06-13       Impact factor: 91.245

3.  MRI Evaluation of Local Extent of Carcinoma Cervix - Is Post Contrast Imaging Needed in Every Case?

Authors:  Joish Upendra Kumar; Ramireddy Harikiran Reddy; Pallavi Sinha; Niveditha Kodali; Vivek Sreekanth
Journal:  J Clin Diagn Res       Date:  2017-05-01

4.  Is Adjuvant Chemotherapy Necessary in Patients with Early Endometrial Cancer?

Authors:  Yuki Iida; Hiroaki Komatsu; Masayo Okawa; Daiken Osaku; Kanae Nosaka; Shinya Sato; Tetsuro Oishi; Fuminori Taniguchi; Tasuku Harada
Journal:  Yonago Acta Med       Date:  2022-02-22       Impact factor: 1.641

5.  Upregulation of PKN1 as a Prognosis Biomarker for Endometrial Cancer.

Authors:  Igor Govorov; Sanaz Attarha; Larysa Kovalevska; Emil Andersson; Elena Kashuba; Miriam Mints
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

6.  Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer.

Authors:  Gaiane M Rauch; Harmeet Kaur; Haesun Choi; Randy D Ernst; Ann H Klopp; Piyaporn Boonsirikamchai; Shannon N Westin; Leonardo P Marcal
Journal:  Radiographics       Date:  2014 Jul-Aug       Impact factor: 5.333

Review 7.  Medical therapy of endometrial cancer: current status and promising novel treatments.

Authors:  Emily K Hill; Don S Dizon
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

8.  The Feasibility of Societal Cost Equivalence between Robotic Hysterectomy and Alternate Hysterectomy Methods for Endometrial Cancer.

Authors:  Neel T Shah; Kelly N Wright; Gudrun M Jonsdottir; Selena Jorgensen; Jon I Einarsson; Michael G Muto
Journal:  Obstet Gynecol Int       Date:  2011-11-15

Review 9.  Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review.

Authors:  Gloria Ravegnini; Francesca Gorini; Eugenia De Crescenzo; Antonio De Leo; Dario De Biase; Marco Di Stanislao; Patrizia Hrelia; Sabrina Angelini; Pierandrea De Iaco; Anna Myriam Perrone
Journal:  Int J Cancer       Date:  2021-11-17       Impact factor: 7.316

10.  Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma.

Authors:  Anna Torres; Kamil Torres; Anna Pesci; Marcello Ceccaroni; Tomasz Paszkowski; Paola Cassandrini; Giuseppe Zamboni; Ryszard Maciejewski
Journal:  BMC Cancer       Date:  2012-08-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.